In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 343 for your search:

Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POI-02818, NIP-02-005, NCT00131313

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22468, 2009-012072-28, NCT01056510

A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25136, NCT01271010

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status

Phase: Phase IV
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25137, NCT01283386

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100917, BENDAMUSCLL4001, NCT01739491

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259

Stem Cell Transplant for Hematological Malignancy

Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930

Fludarabine and Darbepoetin alfa in Treating Older Patients With Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: Geriatric
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL9, EU-20561, AMGEN-GCLLSG-CLL9, EUDRACT-2005-003014-15, NCT00281892

10.

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL7, EU-20559, ROCHE-GCLLSG-CLL7, EUDRACT-2005-003-018-14, NCT00275054

11.

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958

12.

Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Treating Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: CDR0000589684, CHRUT-LLC-2007-SA, CHRUT-PHRN05-CD, INCA-RECF0497, EUDRACT-2007-001015-28, LLC 2007 SA, NCT00645606

13.

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-002, NCT00774345

14.

CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO21004, 2009-012476-28; CLL1, NCT01010061

15.

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Adult
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112517, NCT01039376

16.

Mature B-Cell Lymphoma And Leukemia Study III

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: SJBC3, NCT01046825

17.

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Mabtenance, NCT01118234

18.

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412

19.

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 114242, NCT01313689

20.

Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: 2081-076, NCT01530581

21.

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0117, NCT01539291

22.

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0116, NCT01539512

23.

A Phase 3 Study of the Efficacy and Safety of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CLLM1 Protocol of the GCLLSG, 2011-004698-98, RV-CLL-GCLLSG-0725, NCT01556776

24.

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0115, NCT01569295

25.

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714 AM2)

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P07714, 2011-005186-20, NCT01580228

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map